High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving high-dose chemotherapy before a peripheral blood stem cell transplant stops
the growth of cancer cells by stopping them from dividing or by killing them. Giving
colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the
blood so they can be collected and stored. The stem cells are then returned to the patient to
replace the blood-forming cells that were destroyed by high-dose chemotherapy and radiation
therapy.
PURPOSE: This clinical trial is studying the side effects and how well high-dose chemotherapy
works in treating patients undergoing stem cell transplant for recurrent or refractory
Hodgkin's lymphoma.